not a clue. they stopped communicating matters of interest to the SH. I’ve always felt that the nasdaq talk was gibberish that penny stock ceo’s always say to appease SH before a devastating R/S. And they never shared with the SH their final analysis of the trial data that NRX was forced to give them. off the radar.

More dilution....The management salaries and bonus checks must be paid on the backs of the SH. Someday the fat cats will start doing their job and find a way to generate sales.

"..... Relief Therapeutics plans to use the net proceeds from the private placement for working capital and other general corporate purposes."

https://finance.yahoo.com/news/relief-therapeutics-holding-sa-announces-053000386.html

Here is the full items up for vote......... #8 looks like a R/S
I received the proxy to vote on this items TODAY.

https://www.sec.gov/Archives/edgar/data/1809616/000121390023042704/f6k0523ex99-1_universe.htm

This looks like a R/S in their proxy to be be voted on..... is it not ???

As ordinary resolutions, that: conditional upon the approval of the Board of Directors in its sole discretion, with effect as of the date the Board of Directors of the Company may determine: a. authorized, issued and outstanding shares of the Company (collectively, the "Shares") be consolidated by consolidating each 10 Shares of the Company, or such lesser whole share amount as the Board of Directors may determine in its sole discretion, such amount not to be less than 2, into 1 Share of the Company with such consolidated Shares having the same rights.

Acer Therapeutics Inc gets a Sentiment Score of Bullish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $9.67 https://www.investorsobserver.com/news/stock-update/healthcare-stocks-moving-wednesday-pbla-chek-acer-indp-namsw-nams-carm-zlab

In theory, this should help RLFFD. --- Acer Therapeutics Inc gets a Sentiment Score of Bullish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $9.67 https://www.investorsobserver.com/news/stock-update/healthcare-stocks-moving-wednesday-pbla-chek-acer-indp-namsw-nams-carm-zlab

I'm sorry for your losses. I feel your pain. I have transformed from bullish to neutral. I slowly made the switch when this CEO dragged his feet 'out of the gate' when he got the green light to start the FDA P3 trial. He had at least 6 months to prepare while waiting for the FDA signal. Once the green light came he was like ... Duhhh, what do I do next? It then took him months to get his feet off the ground. Then he posts a lot of garbage about the future of 'shrooms'.

IMO, there is a very high probability that the whole chase after EUA was smoke and mirrors in order to sustain a higher PPS for him to dilute into. Over time his shroom dreams fizzled so he became a little more interested in the FDA initiative, but it was too late. COVID is over, and his O/S is growing with no results to show the SH. It doesn't help matters that this CEO has ZERO communication skills.

I tell you how it is. Take it or leave it.

My expectations of penny stock CEO's is very, very minimal. 98% of them are driven by greed, and they will screw over the SH if it benefits them. It is what it is. Swing Trading is the only smart way to trade penny stocks trading below a dime. 98% of the time the CEO's "End" goals are never met. They lure in investors to chase a very low probability dream. They get rich, the common SH loses. This is what I've learned the hard way. I was only in RVVTF for the unlikely event they would win the EUA. Without that, I'm seeing the glass as half empty. JMHO

I've seen many of R/S happen with the o/s at 500m Of course they will use the old excuse that they need it to uplist to the NASDAQ. That's a worn out excuse. They all use it.

OK...nothing wrong with viewing the glass as half full if one is a stuck long. What other choice is there.

Considering this CEO's slowwww track record, I just believe that it will be 2024 or 2025 before the results of a new trial will ever be disclosed to the SH. Over that time, a whole lot of things can happen (good, bad or ugly) behind the curtain with a penny stock like this. I used to be bullish with this. Now I'm neutral (at best). GLTY.

Reason for PPS crash... failure to meet FDA Phase 3 primary endpoint for MANTRA.
https://finance.yahoo.com/news/rain-oncology-announces-topline-results-120000095.html?.tsrc=rss

However, RAIN does have two other drugs in the pipeline, but unfortunately neither one are in Phase 3 trials.
Pipeline....
https://www.rainoncology.com/pipeline

Fundamentals (debt to equity, O/S, etc) are great, and I see no historical record of an R/S.

IMO RAIN is oversold, but the panic selling may not be complete. It should see a gradual (slow) recovery to the upside over time. But without positive news on the FDA front, I see these price levels as setting a new support level for quite some time.

JMHO

Why? Could be a falling knife.

What caused the price to crash in May?

I thought TSOI had more patents than that.

Giovanni...yes, and I've read somewhere that the FDA must recall 2,500+ (maybe this is a little high) drugs every year due to risks of injury. One may ask .... how does this happen? IMO, this happens because of PDUFA. The FDA receives $$$ (PDUFA fees) from every drug that is approved and sold on the market. This is a conflict of interest, and provides the FDA with an incentive to approve drugs that should have never been approved. These fees also result (IMO) in the FDA being biased towards the BPharmas that will generate the highest PFUFA fees....leaving the little biotech (ex: RVVTF, RLFFD, etc) out of the equation.

PDUFA fees came about so as to provide the FDA with $ resources to help expedite the approval of drugs (a good thing for consumers). But instead it's just provided a vehicle for corruption.

Congress should end PDUFA fees, thereby remove the incentive for corruption. IMO RVVTF is too small to generate a enough PDUFA fees to get the attention of the FDA. JMHO

rick...Unfortunately I have to agree with you. That PR clearly implied that a NEW trial is needed IF the FDA approves the new metric goals. They are back to "Base One" I'm afraid. This is several years away from final FDA approval on anything (at best).

With the O/S over 300M and climbing, I just don't see how the salaries and overall compensation plans can be sustained without an R/S in either 2023 or 2024. All bad news I'm afraid. I've seen this happen far too many times with penny stocks.

a little update from an analyst... I don't think they is anything too new her, but ... "develop a defined recruitment plan" - implies that they are back to Base one IMO.

https://www.proactiveinvestors.com/companies/news/1016408/revive-therapeutics-staying-the-course-on-phase-3-trial-of-bucillamine-in-covid-19-patients-after-meeting-with-fda-1016408.html

Significant Institutional Buying occurred 2022 (Qtr3 and Qtr4) and 2023 (Qtr1)
https://finance.yahoo.com/news/81-stake-microcloud-hologram-inc-121326008.html

.............excerpt
With a 81% stake, MicroCloud Hologram Inc. (NASDAQ:HOLO) insiders have a lot riding on the company

Simply Wall St
Sun, May 28, 2023 at 8:13 AM EDT·4 min read

Significant insider control over MicroCloud Hologram implies vested interests in company growth

A total of 5 investors have a majority stake in the company with 58% ownership

Ownership research, combined with past performance data can help provide a good understanding of opportunities in a stock

If you want to know who really controls MicroCloud Hologram Inc. (NASDAQ:HOLO), then you'll have to look at the makeup of its share registry. With 81% stake, individual insiders possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

With such a notable stake in the company, insiders would be highly incentivised to make value accretive decisions.

Johnny, what will you say to Tim after he receives his first FDA approval and the PPS spikes to $1 ?

Unfortunately the IRS only permits 3K write-off per year.

RVVTF has gotten hammered too. They thought they had a covid pill, but the FDA said... 'not so fast'. And there goes their PPS. It wasn't too long ago and they were sitting at 40 cents.

I read it the same way. I was hanging my hat on the EUA. The O/S is grossly toooooo high for a company that has never made a profit. I've always known the O/S was a major risk. So I can't blame the company. I knew what I was getting into. Even if they manage to get to the NASDAQ I don't see how that will help the investors without some great news. I don't believe that the profits from the ACE drug sales will be enough to make a dent. Manage gets their high salaries and stock options on the back of the common shareholders. I'm afraid that more dilution is inevitable and we'll see yet another R/S. Once they do one, the next one is easy. Just being honest here. It would take some major news either on the FDA front or on the revenue front to turn this around. There is always the chance for great news. But if that were the case, WHY are they preparing us for more dilution per the recent PR. I queried this on the www............

Is an increase in share capital good or bad?

An increase in the total capital stock showing on a company's balance sheet is usually bad news for stockholders because it represents the issuance of additional stock shares, which dilute the value of investors' existing shares.

RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders

https://relieftherapeutics.com/newsblog-detail/?newsID=2520845

Yaaa, like news that their subsideary ACER will soon start generating profits off of their new FDA approved drug.

I had iHUB fix the ticker. Now the PPS is correct.

Are you shorting this stock?

BBWolf...might the trial be listed somewhere on this NIH site? I haven't found it, but I may not be looking in the right place. https://clinicalstudies.info.nih.gov/

To be clear..... (PR excerpt):

....the DSMB recommended that the Study be halted early due to statistical significance of the primary endpoint likely NOT going to be met,....

https://relieftherapeutics.com/newsblog-detail/?newsID=2512049

The fat lady has sung. RVVTF now joins the graveyard along with RLFTF and many other biotechs attempting to profit off of COVID. IMO RVV has always been about shrooms anyhow. By his own actions, the CEO has made that clear from day one. I'm sorry for everyone's losses. I took some losses too, but fortunately I exited about the time RLFTF sunk, so I only took a small hit. I predict that within 1-12 months we'll see an R/S (just like what happened to RLFTF). RVVTF is an unprofitable company, and they will need cash to keep afloat. Unfortunately, small foreign biotechs (in this case Swiss and Canadian) have never been on the FDA radar screen IMO. GLTA.

"Averaging Down" is a common tool investors use that gets them into trouble after falling in love with their investments. WE have all been victims of that.

My question is --- if the trial is a failure, will the pps fall further. Or is failure already baked into the current price.

I've always felt that the CEO had fallen in love with his shrooms, and never really gave much priority to Bucillamine as a covid therapy. He had plenty of time to prepare for an FDA green light to proceed, and instead he dragged his feet early on. He did not have his ducks in a row for launching a covid trial. That was my red flag. And the FDA is no longer under pressure to approve EUA applications for covid. Slow you blow, snooze you loose.

A lot of profit taking going on now. There will be volatility as we get closer to the EPS report on May 10.

I missed the boat on this one. I received a very strong insider buy signal but I didn't see it for over 2 weeks.

Pacific Founders Ugp ....Chicago
"INSIDER 4/6/23 BUY $5.5 M at $1.18"

I'm very impressed with the detailed communication to SH !

Small update on OLPRUVA
https://finance.yahoo.com/news/relief-therapeutics-announces-collaboration-partner-051000197.html

This has ALWAYS been about COVID and obtaining EUA for Bucillamine. Everything else is pretty much a joke IMO. And the need for a new COVID treatment has dramatically subsided....I'm sorry to say. There are lots of 'once promising' COVID small biotechs in the COVID graveyard now.

Getting to the NASDAQ will have zero benefit for the SH if the company doesn't have a viable product or service for sale. Lots of wannabes on the NASDAQ that get kicked back to the OTC for that reason. So, unless RAM has some other rabbit up his sleeve, r/s'ing to get to the NASDAQ will be a waste of time and money, and the experiment will cost the SH dearly. This will be RAM's opportunity to 'shine or fail miserably'.

Good question.

They need to stop talking about acquiring and expanding, and start PRing their intentions on generating revenues/profits. Enough is enough. I'm afraid the r/s will simply give them an excuse to keep spending and acquiring with no regard for the SH. Rinse, Repeat.

I don't trust mgmt. They tried to hide the r/s. They only reported it in the SEC documents because they had to. So I can only swing trade this (at best).

what is his alias?

Looking back, I'm sure glad I exited this at 3 bucks after the r/s. An r/s is never good for any investor 98% of the time. Mgmt never issued a PR on the r/s because they didn't want to draw attention to it. That was my red flag!